bs_bs_banner
14
MOGA Annual Scientific Meeting
International Speakers Professor Fatima Cardoso is the Director of the Breast Unit of the Champalimaud Cancer Clinical in Lisbon, Portugal. Dr Cardoso earned her medical degree at the University of Porto in Portugal and completed fellowships in the Translational Research Unit of the Jules Bordet Institute (IJB) in Brussels, Belgium, and the Department of Molecular and Cellular Oncology at MD Anderson Cancer Center in Houston, Texas. She then worked for 10 years as Assistant Professor at the Medical Oncology Clinic of the IJB where, besides her clinical work, she was active in the Translational Research Unit and was responsible for phase II-III trials in breast cancer. She is board certified in medical oncology and internal medicine. Professor Cardoso’s research interests include biology of breast cancer, prognostic and predictive markers of response to systemic therapy, and new anticancer agents. She is actively involved in a number of phase I-III breast cancer clinical trials and served as the scientific director of the international research network TRANSBIG for 7 years (EU Framework VI). Professor Cardoso is actively involved in numerous professional organizations such as the European Society of Medical Oncology (ESMO), the European Cancer Organization (ECCO), European Organization for Cancer Research (EORTC), American Society for Clinical Oncology (ASCO), and American Association for Cancer Research (AACR) where she serves on several committees, is a Board Member and Chair of the National Representatives Committee of ESMO, the current EORTC Secretary General and chair of the EORTC-Breast Cancer Group. She is also the Breast Cancer Program Coordinator of the European School of Oncology and chair of the Advanced Breast Cancer International Consensus Guidelines Conference (ABC). Professor Dr Cardoso is editor-in-chief of The Breast Journal, associate editor of the European Journal of Cancer, and an editorial board member of several other journals. She has received several educational and research grants from the Breast Cancer Research Foundation, ESMO, ECCO, the Portuguese Science and Technology Foundation, the Portuguese League Against Cancer, the Portuguese Ministry of Health, the Free University of Brussels, the Fonds Jean-Claude Heuson, the Fondation Lambeau-Marteau, the Belgian Federation
Against Cancer, the Susan G. Komen Foundation, and the European Union Framework VI Programme. She was awarded the prestigious Order of Santiago de Espada for Scientific Merit, from the President of Portugal, on10 June 2015. Professor Cardoso has authored over 230 publications and has presented her work nationally and internationally. Professor Adil Daud, an oncologist, is a Clinical Professor in haematology and oncology and, Director of Melanoma Clinical Research at the University of Southern California’s Helen Diller Family Comprehensive Cancer Center. A clinical specialist in melanoma and other skin cancers, Professor Daud also directs melanoma research to better understand the biology of melanoma and to develop new treatments for the disease. He has developed and led many clinical trials that have expanded the use of gene therapy for melanoma. Professor Daud earned a medical degree at the Government Medical College in Nagpur, India. He completed an internship and residency in internal medicine at Indiana University Medical Center, followed by a fellowship in haematology-oncology at Memorial Sloan-Kettering Cancer Center. Prior to joining UCSF Medical Center, he was a researcher at the Moffitt Cancer Center in Tampa, Florida for seven years. Professor Daud has won numerous awards, including the American Society for Clinical Oncology’s Young Investigator award and Castle Connolly’s Best Doctors in America award. Professor Hani Gabra is Professor of Medical Oncology and Deputy Head of the Division of Cancer (Clinical); Head of the Molecular Therapeutics Unit and Director of the Ovarian Cancer Action Research Centre at London’s Imperial College. Within the Imperial College Healthcare NHS Trust he is Head of Medical Oncology, Chair of the Cancer Research Committee and is Honorary Consultant Medical Oncologist. He is also Associate Director and Lead of the Cancer Division (Division 1) of the NIHR Clinical Research Network for North West
15
International Speakers
London. Professor Gabra studied Medicine at the University of Glasgow and graduated with a BSc (Hons) in Molecular Biology and MB ChB in 1987. After obtaining MRCP (UK) in 1990, he undertook an MSc in Clinical Oncology and a PhD in Molecular Oncology from the University of Edinburgh. He then completed his specialist training in Cancer Medicine in Edinburgh and was CRUK Clinical Scientist and Consultant Medical Oncologist at the CRUK Edinburgh Medical Oncology Unit from 1998–2003 when he came to Imperial as Chair in Medical Oncology. He is a Fellow of the Royal College of Physicians of Edinburgh and London. As well as leading the Ovarian Cancer Program at Imperial College, Professor Gabra’s laboratory is involved in trying to understand the role of tumour suppressor genes in ovarian cancer, particularly how OPCML regulates networks of receptor tyrosine kinases and how WWOX acts to regulate taxane sensitivity. His clinical / translational interests relate to the understanding of platinum resistance in ovarian cancer, and he has developed several molecular targets whose inhibition can reverse platinum resistance from laboratory to clinic; such targets include AKT, MTOR, HDAC4, STAT1 and the Folate Receptors. Professor Gabra is President of the European Translational Ovarian Cancer Network (EUTROC), a multinational group that undertakes science in ovarian cancer clinical trials, principally in the context of complex phase II clinical trials. He currently sits on the CRUK CTAAC funding committee for the UK and the INCa Scientific Evaluation Committee, Institut National Du Cancer of France. He is on the Editorial Boards of several journals including Gynecologic Oncology and the European Journal of Cancer. Professor Gabra’s research is principally funded by Ovarian Cancer Action, the national ovarian cancer charity. He is also funded by CRUK and EU FP7 as well as translational and clinical trials funding from pharmaceutical collaborations. Professor James Chih-Hsin Yang is a Professor at the Graduate Institute of Oncology, jointappointed at the Graduate Institute of Clinical Medicine and the Graduate Institute of Clinical Pharmacy of College of Medicine, National Taiwan University
(NTUMC). He is currently the Director of Cancer Research Center at NTUMC and serves as the Director for the Department of Medical Research and Deputy Director of the Department of Oncology at the NTUMC Hospital, where he has been a staff member since 1995. Professor Yang received his MD in 1986 and completed his internal medicine residency at the NTUMC Hospital. Between 1992 and 1995 he undertook medical oncology fellowship training at the National Cancer Institute at Bethesda, Maryland. He completed his PhD degree between 1996 and 2000 at the Graduate Institute of Clinical Medicine, NTU. Professor Yang’s research focuses on lung cancer treatment and the mechanism of multidrug resistance of chemotherapy or targeted therapy. His research includes molecular mechanisms of resistance and reversal of resistance to chemotherapeutic agents and tyrosine kinase inhibitors. Professor Yang is a leader in lung cancer clinical studies, especially in the development of epidermal growth factor receptor tyrosine kinase inhibitors. He has been a steering committee member or the principal investigator on many lung cancer global studies. He and other Asian investigators established EGFR TKI as the front line treatment for lung cancer patients with EGFR mutation (IPASS). He is also the global principle investigator (Lux Lung 1,2,3) of several pivotal studies that led to the global approval of second generation irreversible EGFR TKI, afatinib. His active research now focuses on the development of third generation EGFR TKI and target the targeted therapy combination approach for lung cancer patients. Professor Yang is the executive secretary of the Taiwan Lung Cancer Clinical Trial Consortium (TALCC) and has attended many advisory boards for clinical trial preparation and drug development. He served in the editorial boards of The Journal of Clinical Oncology, Annals of Oncology, Lung Cancer and is the current associate editor of The Journal of Thoracic Oncology and Nature Scientific Report. He recently received the Kobayashi Foundation Cancer Research Award in 2012 and the distinguished research award of the National Science Council, Taiwan in 2013.
14
MOGA Annual Scientific Meeting
International Speakers Professor Fatima Cardoso is the Director of the Breast Unit of the Champalimaud Cancer Clinical in Lisbon, Portugal. Dr Cardoso earned her medical degree at the University of Porto in Portugal and completed fellowships in the Translational Research Unit of the Jules Bordet Institute (IJB) in Brussels, Belgium, and the Department of Molecular and Cellular Oncology at MD Anderson Cancer Center in Houston, Texas. She then worked for 10 years as Assistant Professor at the Medical Oncology Clinic of the IJB where, besides her clinical work, she was active in the Translational Research Unit and was responsible for phase II-III trials in breast cancer. She is board certified in medical oncology and internal medicine. Professor Cardoso’s research interests include biology of breast cancer, prognostic and predictive markers of response to systemic therapy, and new anticancer agents. She is actively involved in a number of phase I-III breast cancer clinical trials and served as the scientific director of the international research network TRANSBIG for 7 years (EU Framework VI). Professor Cardoso is actively involved in numerous professional organizations such as the European Society of Medical Oncology (ESMO), the European Cancer Organization (ECCO), European Organization for Cancer Research (EORTC), American Society for Clinical Oncology (ASCO), and American Association for Cancer Research (AACR) where she serves on several committees, is a Board Member and Chair of the National Representatives Committee of ESMO, the current EORTC Secretary General and chair of the EORTC-Breast Cancer Group. She is also the Breast Cancer Program Coordinator of the European School of Oncology and chair of the Advanced Breast Cancer International Consensus Guidelines Conference (ABC). Professor Dr Cardoso is editor-in-chief of The Breast Journal, associate editor of the European Journal of Cancer, and an editorial board member of several other journals. She has received several educational and research grants from the Breast Cancer Research Foundation, ESMO, ECCO, the Portuguese Science and Technology Foundation, the Portuguese League Against Cancer, the Portuguese Ministry of Health, the Free University of Brussels, the Fonds Jean-Claude Heuson, the Fondation Lambeau-Marteau, the Belgian Federation
Against Cancer, the Susan G. Komen Foundation, and the European Union Framework VI Programme. She was awarded the prestigious Order of Santiago de Espada for Scientific Merit, from the President of Portugal, on10 June 2015. Professor Cardoso has authored over 230 publications and has presented her work nationally and internationally. Professor Adil Daud, an oncologist, is a Clinical Professor in haematology and oncology and, Director of Melanoma Clinical Research at the University of Southern California’s Helen Diller Family Comprehensive Cancer Center. A clinical specialist in melanoma and other skin cancers, Professor Daud also directs melanoma research to better understand the biology of melanoma and to develop new treatments for the disease. He has developed and led many clinical trials that have expanded the use of gene therapy for melanoma. Professor Daud earned a medical degree at the Government Medical College in Nagpur, India. He completed an internship and residency in internal medicine at Indiana University Medical Center, followed by a fellowship in haematology-oncology at Memorial Sloan-Kettering Cancer Center. Prior to joining UCSF Medical Center, he was a researcher at the Moffitt Cancer Center in Tampa, Florida for seven years. Professor Daud has won numerous awards, including the American Society for Clinical Oncology’s Young Investigator award and Castle Connolly’s Best Doctors in America award. Professor Hani Gabra is Professor of Medical Oncology and Deputy Head of the Division of Cancer (Clinical); Head of the Molecular Therapeutics Unit and Director of the Ovarian Cancer Action Research Centre at London’s Imperial College. Within the Imperial College Healthcare NHS Trust he is Head of Medical Oncology, Chair of the Cancer Research Committee and is Honorary Consultant Medical Oncologist. He is also Associate Director and Lead of the Cancer Division (Division 1) of the NIHR Clinical Research Network for North West
15
International Speakers
London. Professor Gabra studied Medicine at the University of Glasgow and graduated with a BSc (Hons) in Molecular Biology and MB ChB in 1987. After obtaining MRCP (UK) in 1990, he undertook an MSc in Clinical Oncology and a PhD in Molecular Oncology from the University of Edinburgh. He then completed his specialist training in Cancer Medicine in Edinburgh and was CRUK Clinical Scientist and Consultant Medical Oncologist at the CRUK Edinburgh Medical Oncology Unit from 1998–2003 when he came to Imperial as Chair in Medical Oncology. He is a Fellow of the Royal College of Physicians of Edinburgh and London. As well as leading the Ovarian Cancer Program at Imperial College, Professor Gabra’s laboratory is involved in trying to understand the role of tumour suppressor genes in ovarian cancer, particularly how OPCML regulates networks of receptor tyrosine kinases and how WWOX acts to regulate taxane sensitivity. His clinical / translational interests relate to the understanding of platinum resistance in ovarian cancer, and he has developed several molecular targets whose inhibition can reverse platinum resistance from laboratory to clinic; such targets include AKT, MTOR, HDAC4, STAT1 and the Folate Receptors. Professor Gabra is President of the European Translational Ovarian Cancer Network (EUTROC), a multinational group that undertakes science in ovarian cancer clinical trials, principally in the context of complex phase II clinical trials. He currently sits on the CRUK CTAAC funding committee for the UK and the INCa Scientific Evaluation Committee, Institut National Du Cancer of France. He is on the Editorial Boards of several journals including Gynecologic Oncology and the European Journal of Cancer. Professor Gabra’s research is principally funded by Ovarian Cancer Action, the national ovarian cancer charity. He is also funded by CRUK and EU FP7 as well as translational and clinical trials funding from pharmaceutical collaborations. Professor James Chih-Hsin Yang is a Professor at the Graduate Institute of Oncology, jointappointed at the Graduate Institute of Clinical Medicine and the Graduate Institute of Clinical Pharmacy of College of Medicine, National Taiwan University
(NTUMC). He is currently the Director of Cancer Research Center at NTUMC and serves as the Director for the Department of Medical Research and Deputy Director of the Department of Oncology at the NTUMC Hospital, where he has been a staff member since 1995. Professor Yang received his MD in 1986 and completed his internal medicine residency at the NTUMC Hospital. Between 1992 and 1995 he undertook medical oncology fellowship training at the National Cancer Institute at Bethesda, Maryland. He completed his PhD degree between 1996 and 2000 at the Graduate Institute of Clinical Medicine, NTU. Professor Yang’s research focuses on lung cancer treatment and the mechanism of multidrug resistance of chemotherapy or targeted therapy. His research includes molecular mechanisms of resistance and reversal of resistance to chemotherapeutic agents and tyrosine kinase inhibitors. Professor Yang is a leader in lung cancer clinical studies, especially in the development of epidermal growth factor receptor tyrosine kinase inhibitors. He has been a steering committee member or the principal investigator on many lung cancer global studies. He and other Asian investigators established EGFR TKI as the front line treatment for lung cancer patients with EGFR mutation (IPASS). He is also the global principle investigator (Lux Lung 1,2,3) of several pivotal studies that led to the global approval of second generation irreversible EGFR TKI, afatinib. His active research now focuses on the development of third generation EGFR TKI and target the targeted therapy combination approach for lung cancer patients. Professor Yang is the executive secretary of the Taiwan Lung Cancer Clinical Trial Consortium (TALCC) and has attended many advisory boards for clinical trial preparation and drug development. He served in the editorial boards of The Journal of Clinical Oncology, Annals of Oncology, Lung Cancer and is the current associate editor of The Journal of Thoracic Oncology and Nature Scientific Report. He recently received the Kobayashi Foundation Cancer Research Award in 2012 and the distinguished research award of the National Science Council, Taiwan in 2013.
